The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Open accessAbstract
BACKGROUND: Recent studies have provided a detailed census of genes that are mutated in acute myeloid leukemia (AML). Our next challenge is to understand how this genetic diversity defines the pathophysiology of AML and informs clinical practice. METHODS: We enrolled a total of 1540 patients in three prospective trials of intensive therapy. Combining driver mutations in 111 cancer genes with cytogenetic and clinical data, we defined AML genomic subgroups and their relevance to clinical outcomes. RESULTS: We identified 5234 driver mutations across 76 genes or genomic regions, with 2 or more drivers identified in 86% of the patients. Patterns of co-mutation compartmentalized the cohort into 11 classes, each with distinct diagnostic features and clinical outcomes. In addition to currently defined AML subgroups, three heterogeneous genomic categories emerged: AML with mutations in genes encoding chromatin, RNA-splicing regulators, or both (in 18% of patients); AML with TP53 mutations, chromosomal aneuploidies, or both (in 13%); and, provisionally, AML with IDH2(R172) mutations (in 1%). Patients with chromatin-spliceosome and TP53-aneuploidy AML had poor outcomes, with the various class-defining mutations contributing independently and additively to the outcome. In addition to class-defining lesions, other co-occurring driver mutations also had a substantial effect on overall survival. The prognostic effects of individual mutations were often significantly altered by the presence or absence of other driver mutations. Such gene-gene interactions were especially pronounced for NPM1-mutated AML, in which patterns of co-mutation identified groups with a favorable or adverse prognosis. These predictions require validation in prospective clinical trials. CONCLUSIONS: The driver landscape in AML reveals distinct molecular subgroups that reflect discrete paths in the evolution of AML, informing disease classification and prognostic stratification. (Funded by the Wellcome Trust and others; ClinicalTrials.gov number, NCT00146120.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Splicing factor mutations are common in AMl and other blood malignancies and are often mutually exclusive (Haferlach et al. 2014;Papaemmanuil et al. 2016), indicating that cancers harboring such mutations may rely on an intact splicing machinery for survival (lee et al. 2018).”
From From serendipity to strategy: molecular glue degraders in cancer therapeutics (2025) · cites this paper as Papaemmanuil et al. 2016
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Leukemia is frequently driven by mutations in epigenetic modifiers or signaling master regulators58 that lead to gross alterations of the epigenetic landscape59 and an epigenetic environment widely permissive of activation.”
From Design principles of cell-state-specific enhancers in hematopoiesis (2025) · cites this paper as [58]
In the citing paper
“Particularly in acute myeloid leukemia (AML), a prominent component of the disease is recurrent mutations in spliceosome machinery and genome-wide aberrant splicing events (14)(15)(16)(17).”
From Discovery of a Novel CIP2A Variant (NOCIVA) with Clinical Relevance in Predicting TKI Resistance in Myeloid Leukemias (2021) · cites this paper as [16]
In the citing paper
“We identified 391 out of the 622 curated COSMIC cancer-related and AML-related genes located inside the altered TADs in at least one sample, and more than 100 are recurrent across multiple samples (Extended Data Fig. 3b)4,24,25.”
From Subtype-specific 3D genome alteration in acute myeloid leukaemia (2022) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit‐MacDonald, A., Harris, N. L., Beau, M. M. L., Hellström‐Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,532
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,468
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D. J., Larson, R. A., et al. (2009) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,438
Self-citationGrimwade, D. J., Walker, H., Oliver, F., Wheatley, K., Harrison, C. J., Harrison, G., Rees, J., Hann, I. M., Stevens, R., Burnett, A. K., et al. (1998) · Blood · doi:10.1182/blood.v92.7.2322 · Cited by 2,649
Absolute quantification of somatic DNA alterations in human cancer
Carter, S. L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T. I., Laird, P. W., Onofrio, R. C., Winckler, W., Weir, B. A., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2203 · Cited by 2,031
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H. F., Sun, Z., Racevskis, J., Vlierberghe, P. V., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,990
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 1,007
Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid Leukemia
Wang, M., Yang, C., Zhang, L., & Schaar, D. G. (2017) · Stem Cells International · doi:10.1155/2017/6962379 · Cited by 52
Pleyer, L., Döhner, H., Dombret, H., Seymour, J. F., Schuh, A. C., Beach, C. L., Swern, A. S., Burgstaller, S., Stauder, R., Girschikofsky, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18020415 · Cited by 51
Self-citationRelapsed/refractory acute myeloid leukemia: any progress?
Schlenk, R. F., Müller‐Tidow, C., Benner, A., & Kieser, M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000404 · Cited by 51
Self-citationTargeting histone methyltransferase and demethylase in acute myeloid leukemia therapy
Castelli, G., Pelosi, E., & Testa, U. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s145971 · Cited by 51
Saygin, C., Hirsch, C. M., Przychodzen, B. P., Sekeres, M. A., Hamilton, B. K., Kalaycio, M. E., Carraway, H. E., Gerds, A. T., Mukherjee, S., Nazha, A., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0040-9 · Cited by 51
Current status and trends in the diagnostics of AML and MDS
Shumilov, E., Flach, J., Kohlmann, A., Banz, Y., Bonadies, N., Fiedler, M., Pabst, T., & Bacher, U. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.04.008 · Cited by 52
Duployez, N., Marceau‐Renaut, A., Villenet, C., Petit, A., Rousseau, A., Ng, S., Paquet, A. C., Gonzales, F., Barthélémy, A., Leprêtre, F., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0227-5 · Cited by 53
The Genetic and Molecular Basis for Canine Models of Human Leukemia and Lymphoma
Avery, A. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00023 · Cited by 51
Fenwarth, L., Thomas, X., de Botton, S., Duployez, N., Bourhis, J.-H., Lesieur, A., Fortin, G., Meslin, P.-A., Yakoub‐Agha, I., Sujobert, P., et al. (2020) · Blood · doi:10.1182/blood.2020005524 · Cited by 52
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanisms
Rejeski, K., Duque‐Afonso, J., & Lübbert, M. (2021) · Oncogene · doi:10.1038/s41388-021-01952-w · Cited by 51
Menin Inhibitors in Acute Myeloid Leukemia—What Does the Future Hold?
Swaminathan, M., Bourgeois, W., Armstrong, S. A., & Wang, E. S. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000571 · Cited by 50
Moving toward individualized target-based therapies in acute myeloid leukemia
Bazinet, A., & Kantarjian, H. M. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.11.004 · Cited by 50
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
Tong, Y., Sun, M., Chen, L., Wang, Y., Yan, L., Li, L., Zhang, X., Cai, Y., Qie, J., Pang, Y., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01384-3 · Cited by 52
ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia
Ebner, J., Schmoellerl, J., Piontek, M., Manhart, G., Troester, S., Carter, B. Z., Neubauer, H. A., Moriggl, R., Szakács, G., Zuber, J. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41229-2 · Cited by 50
Su, L., Tan, Y., Lin, H., Liu, X., Yu, L., Yang, Y., Liu, S., Bai, O., Yan, Y., Jin, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23873 · Cited by 50
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma
Maura, F., Bolli, N., Rustad, E. H., Hultcrantz, M. L., Munshi, N. C., & Landgren, O. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.4659 · Cited by 50
Self-citationStengel, A., Shahswar, R., Haferlach, T., Walter, W., Hütter, S., Meggendorfer, M., Kern, W., & Haferlach, C. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020003007 · Cited by 50
TFEB Links MYC Signaling to Epigenetic Control of Myeloid Differentiation and Acute Myeloid Leukemia
Yun, S., Vincelette, N. D., Yu, X., Watson, G. W., Fernandez, M. R., Yang, C., Hitosugi, T., Cheng, C., Freischel, A. R., Zhang, L., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0029 · Cited by 51
Kempf, J., Weser, S., Bartoschek, M. D., Metzeler, K. H., Vick, B., Herold, T., Völse, K., Mattes, R., Scholz, M., Wange, L. E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-84708-6 · Cited by 50
TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation
George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 53
Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma
Maura, F., Rustad, E. H., Yellapantula, V., Łuksza, M., Hoyos, D., Maclachlan, K. H., Diamond, B. T., Greenbaum, B. D., Morgan, G., Lesokhin, A., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0689-0 · Cited by 50
Self-citationYun, S., Geyer, S. M., Komrokji, R. S., Al Ali, N. H., Song, J., Hussaini, M., Sweet, K. L., Lancet, J. E., List, A. F., Padron, E., et al. (2021) · Leukemia · doi:10.1038/s41375-020-0997-4 · Cited by 49
Recently approved therapies in acute myeloid leukemia: A complex treatment landscape
Talati, C., & Sweet, K. L. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.09.001 · Cited by 50
RNA modifications in hematopoietic malignancies: a new research frontier
Qing, Y., Su, R. J., & Chen, J. (2021) · Blood · doi:10.1182/blood.2019004263 · Cited by 51
Guess, T. E., Potts, C. R., Bhat, P., Cartailler, J. A., Brooks, A., Holt, C., Yenamandra, A., Wheeler, F. C., Savona, M. R., Cartailler, J.-P., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0128 · Cited by 50
Huang, B. J., Smith, J. L., Farrar, J. E., Wang, Y., Umeda, M., Ries, R. E., Leonti, A. R., Crowgey, E. L., Furlan, S. N., Tarlock, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33244-6 · Cited by 49
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia
Ling, V., Straube, J., Godfrey, W. A., Haldar, R., Janardhanan, Y., Cooper, L. T., Bruedigam, C., Cooper, E., Shirazi, P. T., Jacquelin, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01755-2 · Cited by 49
Self-citationCD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
Pelosi, E., Castelli, G., & Testa, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032718 · Cited by 49
Advancements and Challenges in the Treatment of AML
Abaza, Y., McMahon, C. M., & Garcia, J. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_438662 · Cited by 49
The clonal origins of leukemic progression of myelodysplasia
Kim, T., Tyndel, M. S., Kim, H., Ahn, J.-S., Choi, S. H., Park, H., Kim, Y.-K., Yang, D.-H., Lee, J.-J., Jung, S.-H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.17 · Cited by 49
Chrétien, A.-S., Fauriat, C., Orlanducci, F., Rey, J., Bouvier, G., Gautherot, E., Granjeaud, S., Demerle, C., Hamel, J.-F., Cerwenka, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17747 · Cited by 49
Lorentino, F., Labopin, M., Bernardi, M., Ciceri, F., Socié, G., Cornelissen, J. J., Esteve, J., Ruggeri, A., Volin, L., Yakoub‐Agha, I., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25231 · Cited by 49
Acute Myeloid Leukemia: from Mutation Profiling to Treatment Decisions
Dinardo, C. D., & Lachowiez, C. A. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00535-7 · Cited by 49
Tsai, C., Tang, J., Tien, F., Kuo, Y., Wu, D.-C., Lin, C., Tseng, M., Peng, Y., Hou, M.-F., Chuang, Y., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003738 · Cited by 49
Jing, Y., Jiang, X., Lei, L., Peng, M., Ren, J., Xiao, Q., Tao, Y., Tao, Y., Huang, J., Wang, L., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02122-2 · Cited by 51
Corneal pathogenesis of Staphylococcus aureus strain Newman.
Dajcs, J. J., Austin, M. S., Sloop, G. D., Moreau, J. M., Hume, E. B. H., Thompson, H. W., McAleese, F., Foster, T. J., & O’Callaghan, R. J. (2002) · PubMed · Cited by 49
Sequencing-based measurable residual disease testing in acute myeloid leukemia
Yoest, J. M., Shirai, C. L., & Duncavage, E. J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00249 · Cited by 48
A clandestine culprit with critical consequences: Benzene and acute myeloid leukemia
Shallis, R. M., Weiss, J. J., Deziel, N. C., & Gore, S. D. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100736 · Cited by 51
Yu, M., Fang, Z., Wang, W., Zhang, Y., Bu, Z., Liu, M., Xiao, X., Zhang, Z., Zhang, X.-M., Cao, Y., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0455-x · Cited by 48
Miao, H. Z., Kim, E., Chen, D., Purohit, T., Kempińska, K., Ropa, J. P., Kłossowski, S., Trotman, W., Danet-Desnoyers, G. A., Cierpicki, T., et al. (2020) · Blood · doi:10.1182/blood.2020006575 · Cited by 48
Gunn, K., Myllykoski, M., Cao, J. Z., Ahmed, M., Huang, B., Rouaisnel, B., Diplas, B. H., Levitt, M. M., Looper, R., Doench, J. G., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0825 · Cited by 57
Shen, W., Heeley, J. M., Carlston, C. M., Acuña‐Hidalgo, R., Nillesen, W. M., Dent, K. M., Douglas, G. V., Levine, K. L., Bayrak‐Toydemir, P., Marcelis, C., et al. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38485 · Cited by 49
Tsai, C., Hou, H., Tang, J., Kuo, Y., Chiu, Y., Lin, C., Liu, C., Tseng, M., Lin, T.-Y., Liu, M.-C., et al. (2017) · Blood Cancer Journal · doi:10.1038/s41408-017-0022-y · Cited by 48
Telomeres and genomic evolution
Baird, D. M. (2018) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0437 · Cited by 51
Rautenberg, C., Pechtel, S., Hildebrandt, B., Betz, B., Dienst, A., Nachtkamp, K., Kondakci, M., Geyh, S., Wieczorek, D., Haas, R. R., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.05.011 · Cited by 48
New insights into the biology of acute myeloid leukemia with mutated NPM1
Brunetti, L., Gundry, M. C., & Goodell, M. A. (2019) · International Journal of Hematology · doi:10.1007/s12185-018-02578-7 · Cited by 48
SPECTRUM AND IMMUNOPHENOTYPIC PROFILE OF ACUTE LEUKEMIA: A TERTIARY CENTER FLOW CYTOMETRY EXPERIENCE
Gupta, N., Pawar, R. N., Banerjee, S., Brahma, S., Rath, A., Shewale, S. P., Parihar, M., Singh, M. K., Arun, S. R., Krishnan, S., et al. (2019) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2019.017 · Cited by 48
Acute myeloid leukemia immunopeptidome reveals HLA presentation of mutated nucleophosmin
Narayan, R., Olsson, N., Wagar, L. E., Medeiros, B. C., Meyer, E. H., Czerwinski, D. K., Khodadoust, M. S., Zhang, L., Schultz, L. M., Davis, M. M., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219547 · Cited by 48
Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects
Gambacorta, V., Gnani, D., Vago, L., & Micco, R. D. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00207 · Cited by 49
Identification of prognostic genes in the acute myeloid leukemia microenvironment
Huang, S., Zhang, B., Fan, W., Zhao, Q., Yang, L., Xin, W., & Fu, D. (2019) · Aging · doi:10.18632/aging.102477 · Cited by 48
Clonal hematopoiesis, aging, and cardiovascular diseases
Pardali, E., Dimmeler, S., Zeiher, A. M., & Rieger, M. A. (2019) · Experimental Hematology · doi:10.1016/j.exphem.2019.12.006 · Cited by 50
CBL mutations drive PI3K/AKT signaling via increased interaction with LYN and PIK3R1
Belizaire, R., Koochaki, S., Udeshi, N. D., Vedder, A., Sun, L., Svinkina, T., Hartigan, C. R., McConkey, M. E., Kovalcik, V., Bizuayehu, A., et al. (2021) · Blood · doi:10.1182/blood.2020006528 · Cited by 49
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration
Cappelli, L. V., Meggendorfer, M., Baer, C. R., Nadarajah, N., Hütter, S., Jeromin, S., Dicker, F., Kern, W., Haferlach, T., Haferlach, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01368-1 · Cited by 50
FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
Ahn, J., & Kim, H. (2022) · Blood Research · doi:10.5045/br.2022.2022017 · Cited by 48
Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing
Mack, E., Marquardt, A., Langer, D., Ross, P., Ultsch, A., Kiehl, M. G., Mack, H. I. D., Haferlach, T., Neubauer, A., & Brendel, C. A. (2018) · Haematologica · doi:10.3324/haematol.2018.194258 · Cited by 47
Quizartinib for the treatment of acute myeloid leukemia
Garcia‐Horton, A., & Yee, K. W. L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801637 · Cited by 47
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
de Leeuw, D. C., Ossenkoppele, G. J., & Janssen, J. J. W. M. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01299-9 · Cited by 47
Peroni, E., Randi, M. L., Rosato, A., & Cagnin, S. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02841-8 · Cited by 51
Nawas, M. T., & Kosuri, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010417 · Cited by 49
Anande, G., Deshpande, N., Mareschal, S., Batcha, A. M. N., Hampton, H. R., Herold, T., Lehmann, S., Wilkins, M. R., Wong, J. W. H., Unnikrishnan, A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0184 · Cited by 49
Functional and epigenetic phenotypes of humans and mice with DNMT3A Overgrowth Syndrome
Smith, A. M., LaValle, T. A., Shinawi, M. S., Ramakrishnan, S. M., Abel, H., Hill, C. A., Kirkland, N. M., Rettig, M. P., Helton, N., Heath, S. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24800-7 · Cited by 50
Bhola, P. D., Mar, B. G., Lindsley, R. C., Ryan, J. A., Hogdal, L. J., Vo, T. T., DeAngelo, D. J., Galinsky, I. A., Ebert, B. L., & Letai, A. G. (2016) · Journal of Clinical Investigation · doi:10.1172/jci82908 · Cited by 46
Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
Hirsch, P., Tang, R., Abermil, N., Flandrin‐Gresta, P., Moatti, H., Favale, F., Suner, L., Lorre, F., Marzac, C., Fava, F., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.159681 · Cited by 46
Hsu, Y.-C., Chiu, Y., Lin, C., Kuo, Y., Hou, H., Tzeng, Y.-S., Kao, C., Chuang, P., Tseng, M., Hsiao, T., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0508-x · Cited by 46
Stengel, A., Kern, W., Meggendorfer, M., Nadarajah, N., Perglerová, K., Haferlach, T., & Haferlach, C. (2017) · Leukemia · doi:10.1038/leu.2017.239 · Cited by 46
Parkin, B. L., Londoño-Joshi, A. I., Kang, Q., Tewari, M., Rhim, A. D., & Malek, S. N. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91964 · Cited by 46
Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
Schick, M., Habringer, S., Nilsson, J. A., & Keller, U. B. (2017) · British Journal of Haematology · doi:10.1111/bjh.14917 · Cited by 46
Stasik, S., Schuster, C., Ortlepp, C., Platzbecker, U., Bornhäuser, M., Schetelig, J., Ehninger, G., Folprecht, G., & Thiede, C. (2018) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2017.12.001 · Cited by 46
Mechanisms and therapeutic prospects of thrombopoietin receptor agonists
Bussel, J. B., Kulasekararaj, A. G., Cooper, N., Verma, A. K., Steidl, U. G., Semple, J. W., & Will, B. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.09.001 · Cited by 46
Mendez, L., Posey, R. R., & Pandolfi, P. P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01162 · Cited by 46
MRD evaluation of AML in clinical practice: are we there yet?
Freeman, S. D., & Hourigan, C. S. (2019) · Hematology · doi:10.1182/hematology.2019000060 · Cited by 46
Bataller, Á., Oñate, G., Díaz‐Beyá, M., Guijarro, F., Garrido, A., Vives, S., Tormo, M., Arnán, M., Salamero, O., Sampol, A., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16857 · Cited by 47
Seipel, K., Marques, M. A. T., Sidler, C., Mueller, B. U., & Pabst, T. (2018) · Haematologica · doi:10.3324/haematol.2018.191650 · Cited by 45
Venetoclax Resistance in Acute Myeloid Leukemia
Garciaz, S., Collette, Y., & Vey, N. (2024) · Cancers · doi:10.3390/cancers16061091 · Cited by 45
The TP53 tumor suppressor gene: From molecular biology to clinical investigations
Baliakas, P., & Soussi, T. (2025) · Journal of Internal Medicine · doi:10.1111/joim.20106 · Cited by 48
Cohesin Mutations in Myeloid Malignancies
Fisher, J. B., McNulty, M., Burke, M. J., Crispino, J. D., & Rao, S. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.02.006 · Cited by 52
Okabe, A., Funata, S., Matsusaka, K., Namba, H., Fukuyo, M., Rahmutulla, B., Oshima, M., Iwama, A., Fukayama, M., & Kaneda, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-08370-7 · Cited by 45
Clinical challenges in de novo pediatric acute myeloid leukemia
Klein, K., de Haas, V., & Kaspers, G. J. L. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1428091 · Cited by 45
Grimm, J., Bill, M., Jentzsch, M., Beinicke, S., Häntschel, J., Goldmann, K., Schulz, J. C., Cross, M. A., Franke, G., Behre, G., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0413-0 · Cited by 46
Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia
Yang, F., Anekpuritanang, T., & Press, R. D. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00443-9 · Cited by 45
The genomics of acute myeloid leukemia in children
Conneely, S. E., & Rau, R. E. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09846-1 · Cited by 45
Long, L., Assaraf, Y. G., Lei, Z., Peng, H., Yang, L., Chen, Z., & Ren, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100703 · Cited by 47
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia
Lin, W., Fordham, S. E., Hungate, E. A., Sunter, N. J., Elstob, C. J., Xu, Y., Park, C., Quante, A. S., Strauch, K., Gieger, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26551-x · Cited by 46
How I treat with maintenance therapy after allogeneic HCT
DeFilipp, Z. M., & Chen, Y. (2022) · Blood · doi:10.1182/blood.2021012412 · Cited by 45
MicroRNA21 and the various types of myeloid leukemia
Panagal, M., R., S. K. S., Sivakurunathan, P., Biruntha, M., Karthigeyan, M., Gopinathe, V., Sivakumare, P., & Sekar, D. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0025-2 · Cited by 44
Novel Agents for Acute Myeloid Leukemia
Luppi, M., Fabbiano, F., Visani, G., Martinelli, G., & Venditti, A. (2018) · Cancers · doi:10.3390/cancers10110429 · Cited by 45
Walter, R. B., & Estey, E. H. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100679 · Cited by 45
Weng, G., Zhang, Y., Yu, G., Luo, T., Yu, S., Xu, N., Sun, Z., Lin, D., Deng, L., Liang, X., et al. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13581 · Cited by 44
Jaramillo, S., & Schlenk, R. F. (2023) · Haematologica · doi:10.3324/haematol.2022.280802 · Cited by 44
Self-citationLawson, H., Holt‐Martyn, J. P., Dembitz, V., Kabayama, Y., Wang, L. M., Bellani, A., Atwal, S., Saffoon, N., Durko, J., van de Lagemaat, L. N., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00761-w · Cited by 45
Benefits for children with suspected cancer from routine whole-genome sequencing
Hodder, A., Leiter, S. M., Kennedy, J., Addy, D., Ahmed, M., Ajithkumar, T., Allinson, K. S. J., Ancliff, P. J., Bailey, S., Barnard, G., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03056-w · Cited by 47
Cortes, J. E. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01617-7 · Cited by 44
Hernandez, M., Osorio-Marulanda, P. A., Catalina, M., Loinaz, L., Epelde, G., & Aginako, N. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1576290 · Cited by 44
Enhancer dysfunction in leukemia
Bhagwat, A. S., Lu, B., & Vakoc, C. R. (2018) · Blood · doi:10.1182/blood-2017-11-737379 · Cited by 45
Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies
Yang, S., Li, H., Xu, L., Deng, Z., Han, W., Liu, Y., Jiang, W., & Zu, Y. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.08.023 · Cited by 46
Clinical use of FLT3 inhibitors in acute myeloid leukemia
Sutamtewagul, G., & Vigil, C. E. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s171640 · Cited by 44
Acute myeloid leukemia and NK cells: two warriors confront each other
Raneros, A. B., López‐Larrea, C., & Suárez-Álvarez, B. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1539617 · Cited by 44
Mechanisms of leukemic transformation in congenital neutropenia
Link, D. C. (2018) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000479 · Cited by 45
Clonal hematopoiesis: Pre-cancer PLUS
Silver, A. J., & Jaiswal, S. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2018.12.003 · Cited by 46
Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML
Jakobsen, J. S., Laursen, L. G., Schuster, M. B., Pundhir, S., Schoof, E. M., Ge, Y. C., D’Altri, T., Vitting‐Seerup, K., Rapin, N., Gentil, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw4304 · Cited by 49
Self-citation
Metadata
- Authors
- Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., Gundem, G., Van Loo, P., Martincorena, I., Ganly, P., Mudie, L., McLaren, S., O’Meara, S., Raine, K., Jones, D. R., Teague, J. W., Butler, A. P., Greaves, M. F., Ganser, A., Döhner, K., Schlenk, R. F., Döhner, H., & Campbell, P. J.
- Affiliations
- European Bioinformatics Institute (GB)
- Wellcome Sanger Institute (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-06-09
- Volume
- 374
- Issue
- 23
- Pages
- 2209-2221
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4979995
- OpenAlex
- W2419140434
- Cited by
- 4,350
- References
- 40
- Citations by year
- 2026: 345 · 2025: 403 · 2024: 468 · 2023: 460 · 2022: 551 · 2021: 583 · 2020: 481 · 2019: 415 · 2018: 286 · 2017: 282 · 2016: 63
- FWCI
- 331.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- Wellcome Trust (103858/Z/14/Z, 105104, 077012/Z/05/Z, 077012, 103858, 105104/Z/14/Z, WT088340MA)
- Francis Crick Institute (10202)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- acute myeloid leukemia, driver mutations, genomic subgroups, prognostic stratification, TP53 mutation, aneuploidy, NPM1 mutation, IDH2 mutation, gene-gene interaction, co-mutation patterns, overall survival, intensive treatment
- MeSH terms
- DNA Methyltransferase 3A, Nucleophosmin, Adult, DNA (Cytosine-5-)-Methyltransferases, DNA Mutational Analysis, Epistasis, Genetic, Genotype, Humans, Middle Aged, Mutation, Nuclear Proteins, Prognosis, Prospective Studies, RNA Splicing, Leukemia, Myeloid, Acute, Proportional Hazards Models, Survival Analysis, Intracellular Signaling Peptides and Proteins, Gene Fusion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
